Latest Lower urinary tract symptoms Stories
NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH).
SAN FRANCISCO, June 1 /PRNewswire/ -- Nocturia, defined as two or more urinations (voids) per night, may be a more serious condition than widely thought, according to the findings of three new studies.
A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy.
CONCORD, Calif., May 18 /PRNewswire/ -- Researchers at Johns Hopkins University have developed what could be a promising new test to help determine the aggressiveness of prostate cancer, says a Bay Area urologist who specializes in treating the disease, although patients may not realize any benefits for another decade or longer.
In the July issue of European Urology, the scientific journal of the European Association of Urology (EAU), S. Eggener et al. discussed in a recent study the significance and impact of focal therapy for low-risk cancer patients.
BARCELONA, Spain, April 19, 2010 /PRNewswire/ -- - Studies Reinforce Serious Associated Risk of Nocturia Study results discussed today at the European Association of Urology (EAU) Congress in Barcelona have reinforced the association between nocturia and a greater risk of falls and mortality. In a population-representative study in Japan by Nakagawa et al , it was concluded that adults who suffered from nocturia (defined as two or more episodes of voids/urination per night) had...
WALTHAM, Mass., Feb.
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the US than in a European randomized trial because of lower screening sensitivity.
WALTHAM, Mass., Jan.
SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).